Sandy Srinivas, MD, on Managing Metastatic Castration-Resistant Prostate Cancer
NCCN 2021 Virtual Annual Conference
Sandy Srinivas, MD, of Stanford Cancer Institute, discusses the increasing number of ways to deliver life-prolonging therapy to patients with advanced prostate cancer, including more accurate imaging techniques; PET tracers to help better detect, diagnose, and treat disease; PARP inhibitors for BRCA and other mutations; and new sequencing of drugs.
The ASCO Post Staff
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the many considerations when caring for patients with head and neck cancers, such as dental and nutritional issues; side effects from radiation, including necrosis of the bone; oral health; problems with speech; and the concerns of younger patients who may have to cope with the sequelae of treatment such as altered function or disfigurement for years to come.
The ASCO Post Staff
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treatments for patients with HER2-positive breast cancer; newly approved combination therapies such as tucatinib plus capecitabine plus trastuzumab, margetuximab plus chemotherapy, and neratinib plus capecitabine; and recommendations for third line and beyond.
The ASCO Post Staff
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role of checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.
The ASCO Post Staff
Thomas K. Varghese, Jr, MD, of Huntsman Cancer Institute at the University of Utah, summarizes a panel discussion on how the COVID-19 pandemic has interrupted cancer screenings, when telemedicine works and when it doesn’t, opening alternative care sites in the community, and the emotional and mental toll the coronavirus has taken on health-care providers.
The ASCO Post Staff
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the latest data on treating patients with multiple myeloma, including standard-of-care induction before stem cell transplant; the role of quadruplet induction; long-term results with the combination of daratumumab, lenalidomide, and dexamethasone in those who are ineligible for stem cell transplant; CAR T-cell engagers; and the need for more research on how immunotherapy fits in the sequence of treatments.
